Equities Analysts Offer Predictions for DMAC FY2029 Earnings

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) – Equities research analysts at HC Wainwright raised their FY2029 earnings estimates for shares of DiaMedica Therapeutics in a report issued on Thursday, May 15th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of $0.08 for the year, up from their prior estimate of $0.06. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for DiaMedica Therapeutics’ current full-year earnings is ($0.59) per share.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.18) EPS for the quarter, hitting analysts’ consensus estimates of ($0.18). During the same quarter in the prior year, the company earned ($0.14) EPS.

DiaMedica Therapeutics Stock Performance

NASDAQ:DMAC opened at $4.20 on Friday. The company has a 50-day moving average of $4.13 and a 200-day moving average of $5.00. The company has a market capitalization of $180.00 million, a price-to-earnings ratio of -7.50 and a beta of 1.29. DiaMedica Therapeutics has a 52 week low of $2.14 and a 52 week high of $6.82.

Hedge Funds Weigh In On DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in DMAC. Cornerstone Wealth Management LLC bought a new position in DiaMedica Therapeutics during the 1st quarter valued at about $62,000. Balyasny Asset Management L.P. bought a new position in DiaMedica Therapeutics during the 4th quarter valued at about $79,000. Y Intercept Hong Kong Ltd bought a new position in DiaMedica Therapeutics during the 4th quarter valued at about $81,000. Raymond James Financial Inc. bought a new position in DiaMedica Therapeutics during the 4th quarter valued at about $83,000. Finally, Bank of Montreal Can bought a new position in DiaMedica Therapeutics during the 4th quarter valued at about $84,000. 10.12% of the stock is owned by institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.